Skip to content

Fat Loss & Metabolic Health

What is MOTS-C, and how is it classified within mitochondrial-derived peptides?

The question in the title is deceptively simple, and it hides two very different tasks. The first — “what is MOTS-c?” —…

GLP-1 Peptides for PCOS Insulin Resistance: What Is Proven

Retatrutide has never been tested in PCOS, and the wider GLP-1 class has only small, short trials to show for it. As…

How Does AOD-9604 Influence Lipolysis Without Altering IGF-1 Signaling Pathways?

Short answer: AOD-9604 is the fat-mobilising tail of growth hormone with the growth-promoting part cut away, and in rodents that separation genuinely…

How does Semaglutide activate GLP-1 receptors in metabolic research models?

Semaglutide’s Mechanism of Action, in Plain Terms Semaglutide is a long-acting copy of GLP-1, a gut hormone your body releases after you…

What Evidence Shows MOTS-C Modulates Glucose Homeostasis In Various Conditions?

No human trial has shown that MOTS-c lowers blood sugar. That is the single most important fact about this peptide, and it…

Retatrutide for Type 2 Diabetes: A1C and Weight Results

In TRIUMPH-2, the phase 3 trial in 1,152 adults with type 2 diabetes and obesity or overweight, retatrutide cut A1C by up…

Does AOD-9604 Burn Fat Without Losing Lean Muscle?

No — not in humans, and the reason is specific. When AOD-9604 was finally taken into an adequately powered, randomized, placebo-controlled obesity…

How Much Weight Do You Lose on Orforglipron? ATTAIN Trial Results

In the pivotal ATTAIN-1 trial, adults with obesity taking orforglipron 36 mg lost an average of 12.4 percent of their body weight —…

How Do Semaglutide Trials Demonstrate Its Role in Long-Term Obesity Treatment?

Across the STEP program, semaglutide 2.4 mg weekly produced roughly 15% mean weight loss at 68 weeks; in STEP 1, 86.4% of…

What Are the Key Findings on Retatrutide for Managing Obesity and Metabolic Health?

Retatrutide 12 mg produced a mean weight reduction of about 28% at 80 weeks in the pivotal phase 3 TRIUMPH-1 obesity trial,…